Display options
Cite
Dignass A, Schnabel R, Romatowski J, et al. Efficacy and safety of a novel high-dose mesalazine tablet in mild to moderate active ulcerative colitis: a double-blind, multicentre, randomised trial. United European Gastroenterol J. 2017;6(1):138-147doi: 10.1177/2050640617703842.
Dignass, A., Schnabel, R., Romatowski, J., Pavlenko, V., Dorofeyev, A., Derova, J., Jonaitis, L., Dilger, K., Nacak, T., Greinwald, R. (2018). Efficacy and safety of a novel high-dose mesalazine tablet in mild to moderate active ulcerative colitis: a double-blind, multicentre, randomised trial. United European gastroenterology journal, 6(1), 138-147. https://doi.org/10.1177/2050640617703842
Dignass, Axel, et al. "Efficacy and safety of a novel high-dose mesalazine tablet in mild to moderate active ulcerative colitis: a double-blind, multicentre, randomised trial." United European gastroenterology journal vol. 6,1 (2018): 138-147. doi: https://doi.org/10.1177/2050640617703842
Dignass A, Schnabel R, Romatowski J, Pavlenko V, Dorofeyev A, Derova J, Jonaitis L, Dilger K, Nacak T, Greinwald R. Efficacy and safety of a novel high-dose mesalazine tablet in mild to moderate active ulcerative colitis: a double-blind, multicentre, randomised trial. United European Gastroenterol J. 2018 Feb;6(1):138-147. doi: 10.1177/2050640617703842. Epub 2017 Mar 30. PMID: 29435324; PMCID: PMC5802664.
Copy Download .nbib Format: NLM
Share it on

United European Gastroenterol J. 2018 Feb;6(1):138-147. doi: 10.1177/2050640617703842. Epub 2017 Mar 30.

Efficacy and safety of a novel high-dose mesalazine tablet in mild to moderate active ulcerative colitis: a double-blind, multicentre, randomised trial.

United European gastroenterology journal

Axel Dignass, Robert Schnabel, Jacek Romatowski, Vladimir Pavlenko, Andrey Dorofeyev, Jelena Derova, Laimas Jonaitis, Karin Dilger, Tanju Nacak, Roland Greinwald,

Affiliations

  1. Department of Medicine 1, Agaplesion Markus Krankenhaus, Frankfurt am Main, Germany.
  2. Pannónia Magánorvosi Centrum Kft, Budapest, Hungary.
  3. Gastromed sc, Bialystok, Poland.
  4. State Budgetary Educational Institution of Higher Professional Education, Stavropol, Russian Federation.
  5. Regional Bowel Diseases Centre, Donetsk State Medical University, Donetsk, Ukraine.
  6. Latvian Maritime Medical Centre, Riga, Latvia.
  7. Department of Gastroenterology, Lithuanian University of Health Sciences, Kaunas, Lithuania.
  8. Drug Safety, Dr Falk Pharma GmbH, Freiburg, Germany.
  9. Clinical Research and Development Department, Dr Falk Pharma GmbH, Freiburg, Germany.

PMID: 29435324 PMCID: PMC5802664 DOI: 10.1177/2050640617703842

Abstract

BACKGROUND: Adherence to mesalazine treatment is essential for the successful treatment of ulcerative colitis.

OBJECTIVE: The objective of this study was to compare the efficacy, safety and preference of a novel high-dose 1000 mg mesalazine tablet versus conventional treatment for ulcerative colitis remission.

METHODS: This pivotal phase III trial compared one 1000 mg mesalazine tablet (M1000 group) versus two registered 500 mg mesalazine tablets (M2x500 group), both taken three times daily, in patients with mild to moderately active ulcerative colitis. The primary efficacy variable was clinical remission at week 8.

RESULTS: A total of 306 patients were considered for intent-to-treat analysis. Clinical remission was achieved in 45.0% of the patients in the M1000 group versus 41.9% in the M2x500 group (

CONCLUSIONS: The novel high-dose 1000 mg mesalazine tablet is effective, non-inferior to the registered 500 mg mesalazine tablet, and safe for ulcerative colitis treatment. It was preferred by a majority of patients and may improve ulcerative colitis treatment adherence.

Keywords: Mesalazine; adherence; efficacy; randomised; ulcerative colitis

References

  1. Aliment Pharmacol Ther. 2013 Apr;37(8):767-75 - PubMed
  2. Scand J Gastroenterol. 2006 Oct;41(10):1196-203 - PubMed
  3. Am J Gastroenterol. 2000 May;95(5):1263-76 - PubMed
  4. Pharmacoeconomics. 1993 Nov;4(5):353-65 - PubMed
  5. Clin Gastroenterol Hepatol. 2003 Jan;1(1):36-43 - PubMed
  6. Cochrane Database Syst Rev. 2012 Oct 17;10:CD000544 - PubMed
  7. Aliment Pharmacol Ther. 2007 Nov 1;26(9):1237-49 - PubMed
  8. Inflamm Bowel Dis. 2012 Aug;18(8):1540-9 - PubMed
  9. BMJ. 1989 Jan 14;298(6666):82-6 - PubMed
  10. J Crohns Colitis. 2015 Aug;9(8):625-32 - PubMed
  11. Gastroenterology. 2007 Feb;132(2):516-26 - PubMed
  12. Gastroenterology. 2007 Feb;132(2):763-86 - PubMed
  13. BMC Gastroenterol. 2013 Jan 30;13:23 - PubMed
  14. Aliment Pharmacol Ther. 2009 May 15;29(10):1114-20 - PubMed
  15. Inflamm Bowel Dis. 2006 Dec;12(12):1107-13 - PubMed
  16. Am J Gastroenterol. 2001 Oct;96(10):2929-33 - PubMed
  17. Cochrane Database Syst Rev. 2012 Oct 17;10:CD000543 - PubMed
  18. Gut. 1991 Feb;32(2):174-8 - PubMed
  19. Aliment Pharmacol Ther. 2010 Aug;32(3):368-76 - PubMed
  20. Aliment Pharmacol Ther. 2006 Jan 15;23(2):303-12 - PubMed
  21. J Crohns Colitis. 2012 Dec;6(10):991-1030 - PubMed
  22. J Crohns Colitis. 2010 Sep;4(3):283-90 - PubMed
  23. Am J Med. 2003 Jan;114(1):39-43 - PubMed
  24. Drugs. 2008;68(18):2601-9 - PubMed
  25. J Crohns Colitis. 2011 Apr;5(2):129-38 - PubMed
  26. Aliment Pharmacol Ther. 2005 Jan 15;21(2):133-40 - PubMed
  27. Cochrane Database Syst Rev. 2016 Apr 21;4:CD000543 - PubMed
  28. Aliment Pharmacol Ther. 2011 Nov;34(9):1115-22 - PubMed
  29. Aliment Pharmacol Ther. 2011 Feb;33(3):313-22 - PubMed
  30. Gut. 2008 Jul;57(7):893-902 - PubMed
  31. J Crohns Colitis. 2014 Jul;8(7):598-606 - PubMed

Publication Types